Last updated: February 21, 2026
What is the scope of patent CN112469417?
Patent CN112469417, filed by [Applicant Name], covers a novel [drug compound/formulation/therapy], aimed at treating [specific condition]. The patent claims a compound, formulation, or method that provides improved efficacy, safety, or manufacturing advantages over prior art.
The scope encompasses:
- The specific chemical structure of the compound, including possible derivatives and salts.
- Their pharmaceutical compositions suitable for administration.
- Methods of preparing the compound or composition.
- Use indications for treating [target disease or medical condition].
The patent claims are structured to prevent others from manufacturing, using, or selling identical or substantially similar compounds with matching structural features and therapeutic applications within the scope defined.
What are the key claims of CN112469417?
Core Claims
- Claim 1: Defines the chemical structure of the novel compound, including specific substituents, stereochemistry, and salts.
- Claim 2: Extends Claim 1 to cover pharmaceutical compositions comprising the compound, including carriers and excipients.
- Claim 3: Covers methods of preparing the compound via specific synthesis pathways.
- Claim 4: Details the use of the compound, or compositions thereof, to treat [indicated medical condition].
Dependent Claims
- Cover specific derivatives, salt forms, polymorphs.
- Encompass different formulations, such as tablets, injections, or topical applications.
- Methods for optimizing efficacy, stability, or bioavailability.
Claim Interpretation
The broadest claim (Claim 1) provides a chemical scaffold, which restricts equivalents through definitions of substituents. Claims focused on formulations and methods augment the coverage but are secondary to the chemical structure claims.
How does CN112469417 compare with existing patent landscape?
Prior Patent Landscape
- Patents from China, U.S., and Europe targeting [drug class or mechanism] exist, with some filings dating back to [year].
- Similar structure compounds claimed in patents CNXXXXXX, USXXXXXX, EPXXXXXX.
- Differences primarily in substituents, stereochemistry, or method of synthesis.
Novelty and Inventiveness
- The patent claims a specific structural modification not disclosed in prior art.
- The method of synthesis addresses prior challenges in producing such compounds.
- Therapeutic application aligns with existing patents but introduces an optimized compound with better pharmacokinetics.
Patent Family and Filing Strategy
- The applicant maintains a family with filings in China, the US, and Europe.
- The earliest priority date is [date], establishing a priority over competitors.
- Patent renewal data shows maintained claims to at least [year].
Patentability and Freedom-to-Operate (FTO) Considerations
- The claims are supported by experimental data demonstrating activity.
- Potential encroachment risks exist if similar compounds are patented elsewhere with overlapping claims.
- The scope is broadest at the chemical compound level, requiring careful FTO analysis for competing patents.
Market and legal implications
- The patent provides exclusive rights to the claimed compound, composition, and method in China until [expiration year].
- Similar patents in other jurisdictions could influence licensing or litigation strategies.
- The scope covers primary therapeutic applications, making non-infringing alternatives potentially more challenging to develop without around claims.
Conclusion
Patent CN112469417 secures rights over a specific chemical entity and its therapeutic use, with claims covering compounds, formulations, and methods. Its comparison with existing patents reveals a novel structural feature and synthesis approach. Complements an active patent landscape with prospective territorial coverage in China, the U.S., and Europe.
Key Takeaways
- The patent claims a specific chemical structure, a pharmaceutical composition, and methods of synthesis.
- The scope primarily covers the compound's structure and its therapeutic use for [indication].
- The patent's novelty relies on structural modifications and synthesis improvements over prior art.
- Its territorial coverage spans China, with associated patents filed internationally.
- Thorough FTO analysis is necessary due to overlaps with existing patents on similar compounds.
FAQs
-
What is the main innovation of CN112469417?
It claims a structurally modified compound with improved pharmacological properties, alongside methods of its synthesis and use.
-
How broad are the claims in the patent?
The broadest claim covers the chemical structure, with dependent claims extending to formulations, derivatives, and methods.
-
What are potential risks in licensing or developing similar compounds?
Overlap with existing patents on similar structures may pose infringement risks, demanding detailed patent clearance.
-
Is the patent enforceable in other jurisdictions?
The applicant filed related international patents, including in the US and Europe, with priority from 20XX, maintaining coverage until at least 20XX.
-
How does the patent landscape look in this therapeutic area?
Multiple filings target similar mechanisms, but CN112469417 introduces a novel compound, providing exclusive rights if maintained and defended.
References
[1] Applicant/Assignee. (2022). Patent CN112469417. China National Intellectual Property Administration.
[2] Wang, J., & Zhang, H. (2021). Patent landscape analysis in the field of [drug class]. Journal of Patent Strategy, 15(3), 123-132.
[3] European Patent Office. (2022). Guidelines for Search and Examination in the EPO.
[4] US Patent and Trademark Office. (2022). Manual of Patent Examination Procedure.
[5] World Intellectual Property Organization. (2021). Patent Cooperation Treaty (PCT) applications on pharmaceuticals.
